GSK’s Blenrep combo meets key survival endpoint in Phase 3 multiple myeloma testnews2024-11-14T11:04:54+00:00November 14th, 2024|Endpoints News|
FDA approves PTC’s ultra-rare disease gene therapynews2024-11-14T05:11:24+00:00November 14th, 2024|Endpoints News|
Danish biotech Gubra touts early weight loss data in hot amylin fieldnews2024-11-13T19:27:48+00:00November 13th, 2024|Endpoints News|
FDA drug inspections have fallen from 2016 peak, GAO saysnews2024-11-13T18:19:08+00:00November 13th, 2024|Endpoints News|
J&J takes 340B fight with federal government to courtnews2024-11-13T16:34:31+00:00November 13th, 2024|Endpoints News|
89bio’s $125M offering; Another FDA hold for Kezarnews2024-11-13T16:10:00+00:00November 13th, 2024|Endpoints News|
Adaptimmune’s second T cell receptor cell therapy for rare sarcomas passes pivotal testnews2024-11-13T16:07:00+00:00November 13th, 2024|Endpoints News|
Primary care unicorn startup Forward Health shuts downnews2024-11-13T15:20:37+00:00November 13th, 2024|Endpoints News|
Metsera raises $215M for studies of GLP-1 and amylin obesity drugsnews2024-11-13T15:07:20+00:00November 13th, 2024|Endpoints News|
Otsuka and ICU Medical forge IV manufacturing network to supply the USnews2024-11-13T14:15:19+00:00November 13th, 2024|Endpoints News|
